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Abstract 
 
Although it is known that deletions or mutations of the SMN1 gene on chromosome 5 cause 
decreased 
levels of the SMN protein in subjects with proximal autosomal recessive spinal muscular 
atrophy (SMA), the exact sequence of pathological events leading to selective motoneuron 
cell death is not fully understood yet. In this review, new findings regarding the dual cellular 
role of the SMN protein (translocation of β-actin to axonal growth cones and snRNP 
biogenesis/pre-mRNA splicing) were integrated with recent data obtained by detailed 
neuropathological examination of SMA and control subjects. A presumptive series of 10 
pathogenetic events for SMA is proposed as follows: (1) deletions or mutations of the SMN1 
gene, (2) increased SMN mRNA decay and reduction in full-length functional SMN protein, 
(3) impaired motoneuron axonoand dendrogenesis, (4) failure of motoneurons to form 
synapses with corticospinal fibers from upper motoneurons, (5) abnormal motoneuron 
migration towards ventral spinal roots, (6) inappropriate persistence of motoneuron apoptosis 
due to impaired differentiation and motoneuron displacement, (7) substantial numbers of 
motoneurons continuing to migrate abnormally (“heterotopic motoneurons”) and entering into 
the ventral roots, (8) attracted glial cells following these heterotopic motoneurons, which form 
the glial bundles of ventral roots, (9) impaired axonal transport of actin, causing remaining 
motoneurons to become chromatolytic, and (10) eventual death of all apoptotic, heterotopic 
and chromatolytic neurons, with apoptosis being more rapid and predominating in the earlier 
stages, with death of heterotopic and chromatolytic neurons occurring more slowly by 
necrosis during the later stages of SMA. According to this model, the motoneuron axonopathy 
is more important for pathogenesis than the ubiquitous nuclear splicing deficit. It is also 
supposed that individually variable levels of SMN protein, together with influences of other 
phenotype modifier genes and their products, cause the clinical SMA spectrum through 
differential degree of motoneuron functional loss. 
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Introduction 
 
The spinal muscular atrophies (SMAs) are a genetically heterogeneous group of inherited 
diseases that cause progressive muscle degeneration (Table 1) [20, 44, 55, 88]. In this review, 
we focus on the most common form, proximal autosomal recessive SMA, which is the second 
leading cause of neuromuscular disease (after muscular dystrophy) and the second most 
common autosomal recessive disease (after cystic fibrosis), with an incidence of at least 1 in 
10,000 live births and a carrier frequency of 1 in 35 to 1 in 50 [25, 78]. Since the initial 
description of SMA at the end of nineteenth century by Guido Werdnig, it has been postulated 
that pathological changes in SMA consist of four major features (the so-called 
“neuropathologic tetrad”): (1) loss of anterior horn cells (α-motoneurons as well as γ-
motoneurons and interneurons), (2) empty cell beds (at locations of neuron loss), (3) glial cell 
bundles in the ventral spinal roots, and (4) heterotopic motoneurons (HMN) [85]. About a 
hundred years later, Melki and collaborators revealed that recessive forms of proximal SMA 
are caused by reduced survival of motor neuron (SMN) protein due to deletions or mutations 
of the SMN1 gene on chromosome 5 [46]. However, it is still not clear why, and how, 
reduced levels of the SMN protein cause such neuropathological changes. The answer to this 
question is obviously related to our understanding of the normal function(s) of the SMN 
protein and particularities of ventral horn neurons development and function. Here, an 
overview of novel findings regarding the cellular functions of SMN protein in motoneurons 
are put in perspective together with a recent detailed description of the neuropathological 
aspects of SMA [76]. Finally, these data are used to propose a possible pathogenetic model. It 
is hoped that this will help elucidating the mechanisms responsible for SMA genotype-
phenotype relationships and serve for future development of possible treatment and 
prevention 
stategies. 
 
Table 1 Types of spinal muscular atrophy in humans (modified from [55]) 
 
 
SMA type Inheritance Gene/Location Phenotype/Symptoms Age at 
onset 
SMA-1 AR SMN1/5q11.2-13.3 Proximal muscle weakness, 
never sit unaided, death usually 
< 2 years 
usually 
< 9 
months 
SMA-2 AR SMN1/5q11.2-13.3 Proximal muscle weakness, sit 
unaided but wheelchair bound, 
most survive to 2nd or 3rd 
decade 
6-18 
months 
SMA-3 AR SMN1/5q11.2-13.3 Proximal muscle weakness, 
walk unaided, slow progression 
with normal lifespan 
usually 
> 48 
months 
Distal SMA AR 11q13 Distal muscle weakness, 
involvement of diaphragm 
2 
months 
– 20 
years 
SMARD AR IGHBP2/11q13.2 Distal lower limb and 
diaphragmatic weakness, 
sensory and autonomic neurons 
also affected  
1-6 
months 
X-linked infantile 
SMA 
X-linked Xp11.3-q11.2 Arthrogryposis, respiratory 
insufficiency, scoliosis, chest 
deformities, LMN loss 
At birth 
Spino-bulbar 
SMA (Kennedy 
disease) 
X-linked Androgen 
receptor/Xq11.2-
12 
Proximal muscle weakness, 
LMN loss, loss of neurons in 
dorsal root ganglia, bulbar 
involvement  
30-50 
years 
Distal SMA-4 AD 7p15 Distal muscle weakness of 
thenar and peroneal muscles  
12-36 
years 
Congenital SMA AD 12q23-24 Arthrogryposis, non-
progressive weakness of distal 
muscles of lower limbs 
At birth 
SMA associated 
with 
mitochondrial 
mutation 
mitochondrial Cytochrome-c 
oxidase (COX) 
Hypotonia, lactic acidosis, 
respiratory distress, 
cardiomyopathia, COX 
deficiency 
At birth 
 
 
 
 
Clinical presentation and diagnosis 
 
Due to the symmetrical loss of spinal cord anterior horn neurons (Fig. 1a, b), SMA is 
characterized by progressive denervation of skeletal muscles. The weakness and atrophy are 
usually first noted for the proximal voluntary muscles of the extremities. During disease 
progression the distal voluntary muscles of the extremities and eventually entire trunk are also 
affected. Diagnosis is confirmed by muscle biopsy, which seems to be very useful particularly 
in case of chronic infantile forms (Fig. 1c, d), electromyography (showing typical 
“denervation pattern”: abnormal spontaneous activity with fibrillations, positive sharp waves 
and increased mean duration and amplitude of motor unit action potentials), MRI of the spine 
and DNA genotyping. Based on age at onset and severity, SMA is classified in several types 
that form the clinical spectrum [59, 93]. The clinical symptoms in all types of SMA include 
hypotonia, symmetrical muscle weakness and atrophy (predominantly 
of the proximal muscles of the shoulder and pelvic girdle), absence of deep tendon reflexes, 
tremor of fingers and hands, fasciculation of the tongue muscles and hyporeflexia with 
contractures of some muscle groups (the diaphragm and extraocular muscles remain 
unaffected until late stages of the disease and there is little or no impairment of sensory 
systems) [35]. These symptoms are thought to be due to selective loss of motoneurons in the 
spinal cord and cranial motor nuclei leading to progressive muscle weakness, atrophy and 
paralysis [32]. In its most severe type (SMA-1, also called Werdnig-Hoffmann disease or 
acute SMA, MIM# 253300), onset is usually before 9 months. Most of the children are 
completely asymptomatic at birth, with symptoms emerging at around 2–4 months after birth. 
Affected infants are hypotonic („floppy”) with weak, thin muscles, and display feeding and 
breathing problems, fail to achieve early motor milestones and are never able to sit. Death 
occurs within the first 2 years of life, usually due to respiratory failure. If symptoms can be 
seen already at birth, some researchers tend to call this form as SMA-0 type. Infants with 
SMA-2 (the intermediate or chronic infantile form, MIM# 253550) have an onset around 3–
15 months with less severe symptoms, but they become progressively weaker with time. Since 
legs are usually weaker than arms, children with SMA-2 may sit but do not learn to ambulate. 
Survival time is longer, but many patients die generally while still in childhood. The third 
type (SMA-3 or Kugelberg-Welander disease, MIM# 253400) has an onset from 4 to 15 
years. Disease onset before the age of 3 years is classified as type IIIa, whereas an age of 
onset beyond 3 years is classified as type IIIb SMA [93]. Weakness is often first noted in the 
proximal leg and shoulder muscles. These children are able to achieve walking and generally 
live into adulthood (44% of the type IIIa and 90% of type IIIb individuals are able to walk by 
the age of 20 years) [93]. SMA-4 is a rare adult form (MIM# 271150) with onset after 30 
years of age. This milder form of the disease may be inherited in either an autosomal 
dominant or rarely autosomal recessive manner. Individuals with this form of the disease have 
a normal life expectancy and may sometimes be difficult to separate from long-duration forms 
of pure lower motor variant of amyotrophic lateral sclerosis [86]. 
 
 
 
 
 
 Fig. 1 a Normal control spinal cord b SMA spinal cord showing loss of anterior horn cells. 
Cresyl-violet stain. (c) and (d) Muscle biopsy of biceps brachii muscle from SMA-1 subject showing 
neurogenic muscle atrophy (c, d) Large groups of circular atrophic muscle fibers 
(arrowheads) mixed with fascicles of hypertrophied fibers (arrow). Haematoxylin-eosin 
stain. Scale bars: (a, b) 100 µm, (c) 20x magnification, (d) 100x magnification. Photomicrographs (a) 
and (b) are reproduced from Šimić et al. [75] with the permission of 
Wolters Kluwer Health (Lippincott Williams and Wilkins) 
 
 
 
 
 
 
 
 
SMN genes and mutations 
 
Nearly all of SMA patients display homozygous deletions, rearrangements or other mutations 
in the telomeric copy of the survival of motor neuron (SMN) gene on chromosome 5q13 [46]. 
Telomeric (SMN1, MIM# 600354) and centromeric (SMN2, MIM# 601627) genes differ by 5 
single nucleotide changes, two of which are in exons 7 and 8 [66]. These differences do not 
alter the sequence of amino acids encoded by these two genes. However, the exon 7 C-to-T 
transition at codon 280 has been shown to be necessary and sufficient for skipping of exon 7 
during alternative splicing of the SMN2 gene [49]. Consequently, about 80–90% of SMN2 
transcripts lack exon 7 and their truncated transcript encodes for a dysfunctional protein that 
lacks the last 16 residues at the C-terminal and is insuYcient to compensate for the loss of 
SMN1 protein [56]. In other words, the fulllength transcripts are predominantly produced by 
SMN1 and not by SMN2 genes. Therefore, mutations in the SMN2 gene do not lead to disease. 
However, since SMN2 gene does give rise to a small number of the full-length SMN 
transcripts, higher numbers of SMN2 copies have been linked to the less severe SMA types 
[25, 38, 52]. In SMA-1, 
often two or sometimes three copies of the SMN2 gene exist and the amount of full-length 
SMN protein is, on average, around 9% of normal levels. In SMA-2, usually three or more 
SMN2 copies are found together with 14% amount of full-length SMN protein. In SMA-3, 
four to eight SMN2 copies are responsible for an average of 18% of normal SMN protein 
amount. When SMN protein levels approach about 23% function of motor neurons is normal. 
Carriers with one functional copy of SMN1 gene who are generally having about 45–55% of 
normal amount of SMN protein are, therefore, asymptomatic. Different copy number of the 
SMN2 gene is thought to occur by random duplication events. However, in a small population 
of SMA patients, the SMN1 gene is converted to the SMN2 gene by replacing exons 7 and 8 
(gene conversion). In SMA-2 and SMA-3 missense point mutations are far more common 
than in SMA-1 type. Moreover, since it has been shown that even diseased siblings with the 
same number of SMN2 genes can have different SMA phenotypes, many researchers thought 
that the SMN locus alone cannot explain the whole genetic basis for phenotypic variability of 
SMA [18, 71]. To identify those putative SMA modifier genes, a transcriptome-wide 
differential expression analysis using total RNA from the lymphoblastoid cell lines derived 
from both unaffected and affected SMN1-deleted siblings was recently carried out by Wirth 
and collaborators [63]. In total, 18 transcripts showed a greater than threefold difference in 
expression, but only plastin 3 (PLS3, MIM# 300131) exhibited statistically significantly 
higher expression in fully asymptomatic siblings of all six SMA-discordant families analyzed 
[63]. All unaffected SMN1-deleted subjects were females and interestingly also the PST3 gene 
is localized on the sex-determining X chromosome. The authors concluded that this is the first 
modifier gene able to fully protect from developing SMA, but despite extensive efforts, the 
exact cause of this gender-specific protection remains largely unknown. Subsequent 
experiments showed that overexpression of PLS3 rescued the axon length and outgrowth 
defects associated with SMN downregulation in motor neurons of SMA mouse embryos and 
in zebrafish [63]. Since it 
has also been found that plastin 3 is highly expressed during neuronal differentiation in spinal 
cord, associates with SMN protein and increases levels of F-actin, which is important for 
axonal outgrowth and guidance, these findings support the view that the involvement of SMN 
in axonal outgrowth and pathfinding may be the major pathogenetic defect in SMA [63]. It 
may be concluded that genotype–phenotype relationship in autosomal recessive SMA is very 
complex. Namely, although nearly all of the affected patients are having the same 
homozygous absence of SMN1 gene, the different copy numbers of SMN2, together with the 
effect(s) of PLASTIN3 and possibly other, yet unknown genes, gives rise to extremely 
variable phenotypes: from congenital SMA (type 0), through SMA types 1–4, to subjects with 
minimal symptoms or even totally unaffected ones [63, 82]. Spinal muscular atrophy without 
mutations in the SMN1 gene has also been associated with mtDNA depletion due to mutations 
of nuclear thymidine kinase 2 gene (TK2, MIM# 188250) that controls mtDNA replication or 
more often with mutations of the cytochrome-c oxidase assembly gene that controls 
respiratory chain complexes (SCO2, MIM# 604377) [36, 81]. While SMN1 gene is highly 
conserved through evolution, 
the SMN2 gene is unique to humans: most other organisms possess a single copy of the SMN 
gene. Yeast, 
worm, fly, zebrafish and mouse models with no functional SMN protein have a uniformly 
embryonic lethal phenotype [72]. Out of several surrogate mouse models developed, the 
strategy of generating SMA mice which express the human SMN2 gene in the presence of 
Smn gene knockout was shown to be quite promising. Mice expressing one copy of SMN2 
died one day after birth and mice with two SMN2 copies survived for 6 days, showing reduced 
number of motor neurons, while mice expressing 8–16 SMN2 copies were completely rescued 
from the SMA phenotype [37]. Most recently, a line of mice that express high levels of a 
SMN transcript lacking exon 7 (SMN∆7) in the SMN2+/+, Smn-/- background was generated 
[45]. These mice confirm the susceptibility of motoneu
days, due to complexing of the SMN∆7 protein with the full-length protein [45]. This model 
is now most commonly being used to test potential therapeutics. Unfortunately, an in vitro 
motor neuronal model of SMA is missing to date. Currently, much effort is given to develop 
such a model using embryonic stem cells differentiating into motoneurons [48]. 
 
 
SMN protein and its functions 
 
Since the functional SMN protein seems to be critical for survival of α-motoneurons, it would 
be of great importance to know its exact cellular function(s). So far, it is known that the SMN 
protein is an unique molecule with many binding partners and possible functions (Table 2). 
The SMN protein has several identified motifs, such as a lysinerich basic region encoded by 
exon 2, a Tudor domain important for RNA processing encoded by exon 3, a polyproline 
region encoded by exons 4 and 5, and region with several tyrosine–glycine pairs encoded by 
exon 6 [73]. Identification of missense mutations in these regions indicates that each of these 
domains may be functionally important [79]. The SMN protein is found in the nucleus and 
cytoplasm of all cells, but most abundantly in α-motoneurons [5, 7, 91]. Within the nucleus, 
the SMN protein forms heteromeric complexes and seems to play an important role in small 
ribonucleoproteins (snRNPs) biogenesis (such as hnRNP U protein and the small RNA 
binding protein) and pre-mRNA processing (splicing) [26, 96]. It is localized in the nuclear 
domains called Cajal bodies (CBs), which are also involved in the biogenesis and recycling of 
splicing 
snRNPs [23]. In SMA, low SMN protein levels result in altered CBs composition and a 
notable separation of SMN protein into distinct nuclear bodies called gems. In severe cases of 
SMA, a dramatic reduction in nuclear gems can be observed [21]. The first suggestion that 
SMN protein might have other important functions than snRNP assembly came from electron-
microscopical analysis of mouse spinal cord that revealed SMN protein present in dendrites 
and axons [64]. Further analysis of the subcellular localization of SMN during retinoic-acid-
induced neuronal differentiation of mouse teratocarcinoma P19 cells demonstrated SMN 
accumulation in growth cone and filopodia in both neuronal- and glial-like cells [24]. 
Moreover, SMN was present at the leading edge of neurite outgrowths, suggesting its specific 
role in axono- and dendrogenesis. Then, SMN protein was found to be present at axon 
branching points and growth cones in cultured motoneurons [24, 39]. 
Table 2 Interactions of the SMN protein with components of SMN complex and other 
interacting partners (modified from [89]) 
  
Core 
components 
 Interaction 
direct (+) 
indirect(-) 
Function 
 Gemin1 (SMN) +  
 Gemin2 (SIP1) + snRNP biogenesis and pre-mRNA 
splicing 
 Gemin3 (DP103) + snRNP biogenesis and pre-mRNA 
splicing 
 Gemin4 (GIP1) - snRNP biogenesis and pre-mRNA 
splicing 
 Gemin5 (p175) + snRNP biogenesis and pre-mRNA 
splicing 
 Gemin6 - snRNP biogenesis and pre-mRNA 
splicing 
 Gemin7 + snRNP biogenesis and pre-mRNA 
splicing 
 Gemin8 - snRNP biogenesis and pre-mRNA 
splicing 
 Unrip - snRNP biogenesis and pre-mRNA 
splicing 
Interacting 
partners of 
SMN 
complex 
 
  
 Sm proteins (B or B', 
D1, D2, D3, E, F and G) 
and LSm1-7 
+ snRNP biogenesis and pre-mRNA 
splicing 
 Fibrillarin and GAR1 + Assembly of snoRNPs 
 Coilin + Recruitment of SMN to Cajal 
bodies 
 ZPR1 (zink-finger 
protein 1) 
+ Caspase activation, apoptosis, 
assembly and maturation of 
snRNP 
 Profilin + Actin dynamics control 
 OSF (osteoclast-
stimulating factor 
+ Osteoclast activity regulation 
 Nucleolin and B23 - Cell growth, proliferation and 
differentiation, PCD, cell surface 
signal transduction  
 RNA helicase A + Transcription 
 RNA polimerase II - Transcription 
 hnRNP Q and R + RNA transport along axons 
 Snurportin and 
importin beta 
+ and - Transport of snRNPs to nucleus 
 Galectin 1 and 3 - snRNP biogenesis and pre-mRNA 
splicing 
 P53 + Apoptosis 
 FGF-2 (fibroblast 
growth factor 2) 
+ Neurotrophic factor for motor 
neurons 
 EWS (Ewing sarcoma) + Transcription 
 Bcl-2 + Antiapoptosis 
 FUSE-binding protein + Transcription and mRNA stability 
regulation 
 PPP4 (protein 
phosphatase 4) 
- Dephosphorylates serine and 
threonine residues 
 TGSI (trimethyl-
guanosine synthase 1) 
+ snRNA cap hypermethylase 
 Rpp20 + Maturation of tRNA and rRNA 
 
 
 
 In a more detailed analysis that Rossoll and collaborators performed in nPC12 cells, is was 
found that Smn colocalizes with hnRNPR in cell bodies and neurite-like proceses [68]. In 
contrast, hnRNP-R lacking the Smn interaction domain localized 
primarily to the nucleus indicating that hnRNP-R is targeted to cell processes by Smn where it 
mediates processes other than pre-mRNA splicing. Furthermore, it was also demonstrated that 
hnRNP-R is present in significantly reduced levels in neurites and growth cones of motor 
neurons from Smn-/-, SMN2 mice compared to Smnt/t;SMN2 motor neurons [68]. The 
interaction between Smn and hnRNP-R was functionally relevant since upregulation of either 
Smn or hnRNP-R resulted in enhanced outgrowth of neurites, which could be suppressed by 
hnRNP-R lacking the Smn interaction domain [68]. By expressing truncated proteins, the 
same authors also showed that this positive effect on neurite outgrowth depends on functional 
Smn as well as on the RNA-binding domain of hnRNP-R. Accordingly, Smn mutant motor 
neurons showed reduced growth cone size. Further experiments confirmed actin as a most 
probable downstream mediator of the Smn–hnRNP–R complex [87]. 
Actin is a major component of outgrowing axons responsible for growth cone motility and 
transport of its mRNA into distal axons and growth cones can be stimulated by neurotrophin 
treatment [10, 87]. In addition to interactions with hnRNP-R and Q [69], SMN has also been 
shown to interact with profilin II, an actin-binding protein [31]. Profilin II is highly expressed 
in brain and spinal cord, where it localizes predominantly to anterior horn neurons [31]. The 
asymmetric SMN staining demonstrated in the germinative neuroepithelium further supported 
a role for SMN in neuronal migration and differentiation [23]. Finally, new approaches to 
study SMN protein function, particularly the use of antisense morpholino and synthetic RNA 
injections to knockdown SMN levels in the zebrafish model of SMA, have confirmed the 
hypothesis that, in addition to its role in snRNP biogenesis, SMN protein has an additional 
and independent function which is critical for motor neuron axon outgrowth [10, 11, 30, 54, 
74]. Moreover, the severity of motor axon defects was shown to correlate with 
decreased survival of the zebrafish, suggesting that SMN protein is not only needed for motor 
neuron outgrowth, but perhaps also in its maintenance of, and interactions with, muscle [11], 
which is further supported by the finding of increased vulnerability of the neuromuscular 
juntions in mouse SMA models [60]. One of the most recent exciting new findings has been 
the identification of an SMN transcript which encodes the axonal-SMN protein which is 
found to be selectively expressed in developing spinal cord motoneurons and mainly localized 
in axons [74]. The presence of diverse types of SMN complexes that have functions in 
neurons, other than its well characterized role to assemble snRNPs was recently further 
confirmed using high-resolution fluorescence of an SMN-Gemin complex in neuronal 
processes and growth cones of embryonic stem cell-derived motor neurons [95]. An attractive 
hypothesis driven from these findings is that the SMN complexes play a role in the assembly 
of localized mRNP complexes needed for axonal growth and synaptogenesis. 
 
 
Neuropathological changes in SMA and proposed pathogenetic model 
 
Based on the published neuropathological data [15, 75, 76], it can be stated that four different 
morphological types of motoneurons exist in the spinal cord of SMA subjects, each probably 
having a different cell fate: 
 
(1) Morphologically normal motoneurons in their normal position: on average 10–20% of 
motoneurons seen during postmortem analysis of SMA-1 subjects. It is supposed that the 
number of these neurons correlates with the amount of SMN protein produced. 
 
(2) Morphologically abnormal motoneurons in their normal position, i.e., chromatolytic 
neurons within anterior spinal grey matter. These neurons die slowly by necrotic cell death 
and comprise about 60–85% of the remaining motoneurons seen at autopsy. 
 
(3) Apoptotic motoneurons within the ventral horns. Although the number of these neurons is 
relatively low 
(on average 2–3% of the remaining neurons seen in SMA-1 subjects), since they die very 
rapidly and disappear 
even faster due to heterophagic elimination by activated microglial cells, their cumulative 
number is probably largely underestimated. 
 
(4) Heterotopic (migratory, displaced) motoneurons (HMN). Unlike controls, SMA patients 
with confirmed 
homozygous deletion of exon 7 in the SMN1 gene display a significant number of HMN at all 
levels of the 
spinal cord [76]. These heterotopic motoneurons are situated all along the ventral outflow of 
the white matter 
and within the ventral roots, have no axon or dendrites, appear hyperchromatic in Nissl-
stained sections and their number positively correlates with clinical severity [76]. It was 
shown that HMN have no synapses, rarely activate microglial cells, and eventually die slowly 
by necrosis [76]. 
 
Taken all the findings together, an integrated model of SMA pathogenesis can be proposed. 
The presumptive 
series of pathological events during the development of SMA according to this model is given 
in Figs. 2 and 3 and follow the sequence below: 
 
(1) Mutations or deletions of the SMN1 gene [8, 46]. 
 
(2) Increased SMN mRNA decay [8] and reduction in functional, full-length SMN protein 
production [47] 
lead to decreased intracellular concentration of oligomerization-competent SMN proteins 
proportional to 
disease severity [50, 92]. 
 
(3) Impaired spinal motoneuron axono- and dendrogenesis [76]. 
 
(4) Failure of motoneurons to form synapses onto the corticospinal fibers of the upper 
motoneurons [15]. 
 
(5) Due to the disturbed differentiation (i.e., impaired dendrite and axon outgrowth) and lack 
of synapse formation many motoneurons continue to migrate along the ventral outflow in the 
anterior direction towards the ventral roots of spinal cord (heterotopic motoneurons) [76]. 
 
(6) In some of these abnormally migrating undifferentiated neurons, apoptotic mode of 
programmed cell death 
program is activated and they rapidly die (because they are immediately being eliminated by 
nearby microglial 
cells, this leaves no biochemical or morphological trace). It seems that apoptosis is 
inappropriately prolonged 
[3, 38, 42, 65, 70, 75, 84, 92], because during the midgestational period this is the normal 
process by which 40–70% of the embryonic motor neurons in the spinal cord undergo 
naturally occurring programmed cell death immediately following the arrival of their axons in 
muscle cells [16, 62, 90].
  
 
 
Fig. 2 The proposed pathogenetic mechanism 
of SMA. A sequence of events during normal 
motoneuron development is given in a and b 
for comparison with SMA (c, d). Schemes a 
and c represent presumed events during early 
prenatal stage, while b and d represent late 
prenatal 
stage. The numbers on the scheme correspond 
to numbers of the proposed pathogenetic steps 
in the text (1–10). A anterior corticospinal 
tract fibers (green), L lateral corticospinal tract 
Wbers (green), blue dots astrocytes, blue lines 
glial bundles, red dots microglial cells, SMA 
spinal muscular atrophy 
 
 
 
(7) The larger part of motoneurons continues its abnormal migration, some being stopped by the 
anterior rim of 
the spinal cord, others migrating even outside the anterior white matter and entering the ventral 
roots [76]. 
 
(8) As a secondary phenomenon, attracted glial cells follow abnormally migrating HMN thus 
forming glial bundles within the ventral roots [14, 29]. 
 
(9) Impaired axonal transport of actin causes remaining motoneurons to become chromatolytic. It 
is the 
author’s speculation that glial bundles of ventral roots may further compromise axoplasmic flow 
of these 
neurons causing a so-called axonal reaction of the central type. 
 
(10) In the end-stage of the disease, all apoptotic, heterotopic and chromatolytic neurons [27] 
eventually die. 
Apoptotic cells do so more rapidly and predominantly during earlier stages of SMA, while 
heterotopic and 
chromatolytic cells die more slowly by necrosis during the later stages of SMA. It is hoped that 
future 
studies will use unbiased stereological methods, to precisely quantify the magnitude of 
motoneuron cell 
loss due to each type of cell death as well as with respect to each particular SMA genotype. 
Within the framework of this model, it is supposed that individually variable levels of SMN 
protein together with influences of other phenotype modifier genes and their products cause 
different types of SMA through differential degree of motoneuron functional loss. 
 
 
 
 
 
 
 
 
SMA treatment and prevention strategies 
 
Treatment and prevention strategies for SMA can be divided in at least five broad groups: (1) use 
of compounds 
that drive SMN2 promoter activity; (2) use of drugs that modulate SMN2 splicing; (3) use drugs 
that stabilize SMN2 mRNA or SMN protein; (4) gene therapy; and (5) stem cell therapy [79]. 
 
Compounds that drive SMN2 promoter activity and activate SMN2 gene expression 
 
As noted previously, there is a strong inverse correlation between SMN protein production from 
the SMN2 gene and disease severity, both in SMA patients [47] and SMA mouse models [28, 58]. 
For the purpose of quantification of SMN protein levels, a cell immunoassay [43] and a two site 
enzyme-linked immunosorbent assay (ELISA) have been developed to measure accurately drug-
induced SMN elevation in model systems, such as skin fibroblast cultures from type I SMA 
patients [53]. It is of importance that the SMN genotypes producing less SMN protein have also 
been shown to increase susceptibility to and severity of sporadic amyotrophic lateral sclerosis 
[83]. The SMN2 gene is regulated by a promoter that is nearly identical in sequence and activity 
to the SMN1 promoter [22, 57]. The level of histone acetylation is determined by the balance of 
activities of histone acetyltransferases, which acetylate histones, and histone deacetylase 
(HDAC), which deacetylate histones. Control of the acetylation state of histones is an important 
epigenetic mechanism regulating gene expression. When the NH2-terminus of core histones is 
acetylated, corresponding chromatine region is more transcriptionally active due to increased 
accessibility of DNA. It has been demonstrated that HDAC 1 and 2 proteins may modulate the 
histone acetylation state at the SMN promoter and determine SMN2 gene expression [41]. One of 
the earliest discovered HDAC inhibitors was sodium butyrate, which was shown to increase full-
length SMN2 transcript levels and SMN protein levels in lymphoblastoid cell lines derived from 
SMA-1 patients [13]. Subsequent studies showed that the same effect can be achived by several 
other HDAC inhibitors, such as phenylbutyrate [2], valproate [8, 80], trichostatin A [4] and 
suberoyl anilide hydroxamic acid [9, 40, 41, 80]. Other drugs that have been proposed to work by 
activating SMN2 gene expression are hydroxyurea [33] and indoprofen [51]. Most of the drugs 
mentioned are currently being studied in clinical trials worldwide. Recently, a screening of 
550,000 different small molecules was performed to identify those that activate SMN2 
promoter present in a motoneuron-like NSC34 cells [40]. None of the 17 different compounds 
were acting as HDAC inhibitors. Two compounds, one indole and one quinazoline were 
confirmed to increase full-length SMN transcript and protein in SMA-derived cells. 
 
 
 
Fig. 3 Illustrative examples for Fig. 2. Letters a–j correspond to pathogenetic events 1–10, respectively. a 
PCR analysis of SMN exon 7, b Western blot analysis of SMN protein, c impaired axono- and 
dendrogenesis of heterotopic spinal motoneurons in SMA d spinal 
motoneuron of SMA patient without synapses (electron microscopy) e heterotopic (migratory) 
motoneurons (arrows) in SMA (cresyl-violet stain) f apoptotic motoneurons (arrowheads) in SMA 
(cresyl-violet stain) g heterotopic (migratory) motoneurons (mmn) in the ventral roots (VR) of SMA 
patient (cresyl-violet stain) h glial bundles of ventral roots (GB) (cresyl-violet stain) i anterior horn of a 
SMA subject: an apoptotic motoneuron engulfed by an ISEL-positive microglial cell (large arrowhead); 
arrow shows weakly ISEL-positive neuron probably representing an early stage of the apoptotic process; 
small arrowheads show ISEL-positive nuclei of microglial cells that appear to be involved in 
neuronophagia of chromatolytic neurons (in-situ end labeling) j neuronophagia of a chromatolytic neuron 
(cresyl-violet stain). Scale bars: c, e, g, h = 20 µm, (d) = 1 µm, (f) = 5 µm, (i, j) = 10 µm. 
Photomicrographs (c), (d), (e), (g) and (h) are reproduced from Šimić et al. [76]. Photomicrographs f, i 
and j are reproduced from Šimić et al. [75], with the permission of Wolters Kluwer Health (Lippincott 
Williams and Wilkins) 
 
 
 
 
Drugs that modulate SMN2 splicing 
 
The mechanisms that direct splicing of the SMN gene transcripts showed that full-length SMN 
transcript is encoded by exons 1, 2a, 2b and 3–8, while exons 1–7 are being translated into SMN 
protein. It seems that there are many exonic and intronic splice enhancer and silencer motifs that 
play role in SMN transcript splicing. After a screen in patient fibroblasts, a chemotherapeutic 
drug aclarubicin was shown to stimulate exon 7 inclusion in SMN2 gene transcripts [2] therefore 
yielding a higher proportion of fulllength SMN protein [25]. Unfortunately, the toxicity profile of 
this drug prohibits its long-term use. Another strategy to enhance exon 7 inclusion is the use of 
synthetic antisense oligonucleotides that bind to SMN2-derived transcripts and promote exon 7 
inclusion during splicing. Although it has been shown that this strategy may work well in vitro 
[12, 77], achieving efficient delivery of these oligonucleotides to motor neurons remains to be an 
unresolved problem. 
 
 
Drugs that stabilize SMN2 mRNA or SMN protein 
 
As it has been shown that in a subset of SMA patients intragenic SMN1 mutations render SMN1 
transcripts susceptible to nonsense-mediated SMN mRNA decay (resulting in mRNA 
degradation), future treatment strategies may also be directed towards increasing SMN mRNA 
stability [8]. One group of the candidate compounds may be aminoglycosides, which stabilize 
SMN2 mRNA by triggering stop codon read through [89]. 
 
Gene therapy for SMA 
 
Since the SMN2 gene is present in the same region of chromosome 5 and is similar in sequence 
to SMN1 except for a T at position +6 of exon 7 that is likely the predominant functional 
difference between the two genes, an approach has been developed to use single-stranded 
oligonucleotides (ODN) to repair genes within the context of the native chromosome. Indeed, 
using SMN2-sequence-specific ODN to direct the exchange of a T to a C in an SMA skin 
fibroblast cell line from a type 1 patient was shown to increase production of full-length SMN 
mRNA, measured by qRTPCR, and SMN protein, measured by Western blotting [19]. However, 
the technical difficulty of gene delivery, together with problems related to random insertion of the 
therapeutic gene, still represent the major obstacles for its use in treatment of SMA patients. 
Stem cell therapy for SMA 
 
Embryonic stem (ES) cells are omnipotent cells that can be directed to differentiate into motor 
neurons. Transplantation of such differentiated ES into the spinal cord of rats with induced 
motoneuron injury showed promising results because these cells survived and produced axons 
that were able to grow into the ventral root [34]. With the growing understanding of ES cell 
biology and SMA pathogenesis, ES cells-based therapy is moving closer to clinical application 
[17, 48, 61, 67]. 
 
 
Two hypotheses on SMA pathogenesis 
 
Based on the data available in the literature two main hypotheses about the pathogenesis of SMA 
prevail. The first one is that severe SMN deficiency causes widespread premRNA splicing 
defects in numerous mouse transcripts of diverse genes, preferentially those containing a large 
number of introns [96]. Since only a large degree of SMN decrease (>80%) is required to cause a 
significant change in the levels of snRNAs or cause cell death in cultured cells, this suggests that 
cells normally contain a large excess capacity of SMN complex to maintain their normal 
inventory of snRNAs. According to this hypothesis, SMA is a general splicing disease 
not restricted to motor neurons. However, the degree of snRNAs reduction is not uniform across 
different tissues and cell types. Within this framework it is speculated that the affected motor 
neurons, being large and high energy requiring cells, would have a lower tolerance for depleted 
SMN levels and are uniquely sensitive. 
The alternative hypothesis on pathogenesis of SMA is that the disease is a consequence of a 
motor neuron specific function of the SMN protein. This hypothesis stems from observations 
demonstrating the accumulation of the SMN protein in the axons and growth cones of motor 
neuron like cells in vitro and anterior horn cells in vivo [6, 7, 10, 11, 24, 30, 54, 64, 68, 74, 94], 
and its interaction with the heterogeneous nuclear riboprotein Q and R (hnRNP-R) and β-actin 
mRNA, targeting them into the growth cones [68]. According to the pathogenetic model 
proposed in this review, the selective motoneuron axonopathy appears to be far more important 
than ubiquitous nuclear splicing deficit. 
 
 
 
Conclusion 
 
In conclusion, recent molecular and neuropathological findings suggest that impaired outgrowth 
of motoneurons’ axon and dendrites with subsequent abnormal migration may represent the early 
key events of SMA pathogenesis and are responsible for all of the subsequent pathological 
changes observed in these cases. It is supposed that individually variable levels of SMN protein, 
together with influences of other phenotype modifier genes and their products, cause the clinical 
SMA spectrum through differential degree of motoneuron functional loss. The dynamics of the 
described sequence of interrelated events still needs to be fully elucidated. Hopefully the present 
review will help building more efficient treatment and prevention strategies for SMA. 
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